Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.79 |
| ▸ | PKM | P14618 | 5/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.79 |
| ▸ | NPC1 | O15118 | 5/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.63 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.59 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.59 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604280 | 1.00 | MAPT (0.79) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL12257967 | 0.93 | MAPT (0.90) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL977480 | 0.88 | MAPT (1.00) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL4400320 | 0.88 | MAPT (1.00) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL1929871 | 0.86 | PKM (0.82) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL9231010 | 0.86 | MAPT (0.77) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL11973097 | 0.86 | MAPT (0.77) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL9231011 | 0.86 | MAPT (0.77) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL657047 | 0.86 | MAPT (0.77) | MAPTRAB9APKMKDM4ENPC1 | |
| SCHEMBL6793176 | 0.86 | RAB9A (0.77) | MAPTRAB9APKMKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228795-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-07-17 | — | — | US | disclosed |
| CN-119677514-A | Estrogenic compounds and methods of use | 益特瑞恩公司 | 2025-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228795-A1 | ESTROGENIC COMPOUNDS AND METHODS OF USE | ESR1, ESR2, CYP19A1 | MAPT 2361/4885RAB9A 3934/4885PKM 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.